CG
JUNO

Cutler Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

Cutler Group’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-19,100
Closed -$21K – 5813
2017
Q4 		$21K Sell
19,100
-30,000
-61% -$1.5M ﹤0.01% 2539
2017
Q3 		$42K Sell
49,100
-3,000
-6% -$102K ﹤0.01% 2414
2017
Q2 		$90K Buy
52,100
+5,500
+12% +$136K ﹤0.01% 1959
2017
Q1 		$142K Buy
46,600
+10,700
+30% +$230K 0.01% 1450
2016
Q4 		$331K Sell
35,900
-18,600
-34% -$455K 0.01% 949
2016
Q3 		$202K Buy
54,500
+9,800
+22% +$305K 0.01% 1204
2016
Q2 		$394K Buy
44,700
+5,400
+14% +$224K 0.02% 716
2016
Q1 		$331K Sell
39,300
-2,000
-5% -$69.7K 0.02% 719
2015
Q4 		$374K Buy
+41,300
New +$2.05M 0.02% 782

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Cutler Group's JUNO Position: Q1 2018 in Review

Cutler Group sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 16,700 shares — an estimated $763K sold.

Cutler Group first reported a position in JUNO in Q4 2015 and held it in 9 quarters. The position peaked at $890K in Q2 2016. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Cutler Group reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Cutler Group sold 16,700 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $763K.
  • Cutler Group first reported a position in Juno Therapeutics, Inc. in Q4 2015 and held it in 9 quarters.
  • Cutler Group's Juno Therapeutics, Inc. position peaked at $890K in Q2 2016.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Cutler Group's 13F filing for Q1 2018, filed 11 May 2018.